Drug Trial Radar · NCT04764851
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
Last checked: Nov 19, 2026Latest source record: May 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
30
Actual
Start
Feb 18, 2021
Primary completion
Apr 2, 2021
Study completion May 7, 2021
Sponsor
- Lead sponsor
- Emalex Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; Nuventra, Inc.
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
Conditions
- Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/dayDrug
oral tablet
Cohort 1 Probe CocktailCombination product
dextromethorphan, caffeine, omeprazole, and midazolam
Cohort 2 Probe CocktailCombination product
dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
Cohort 3 Probe CocktailCombination product
bupropion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipamTime frame: Up to Day 18
- Cmax of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipamTime frame: Up to Day 18
- Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
- Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
- Cmax of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
- Cmax oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
- Cmax of dabigatran in the presence of ecopipamTime frame: Up to Day 18
- Cmax of dabigatran in the absence of ecopipamTime frame: Up to Day 18
- Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 18
- Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 18
- Cmax of rosuvastatin in the presence of ecopipamTime frame: Up to Day 18
- Cmax of rosuvastatin in the absence of ecopipamTime frame: Up to Day 18
- Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 18
- Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of dabigatran in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of dabigatran in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of rosuvastatin in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of rosuvastatin in the absence of ecopipamTime frame: Up to Day 18
- AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUClast of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUClast of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUClast of dabigatran in the presence of ecopipamTime frame: Up to Day 18
- AUClast of dabigatran in the absence of ecopipamTime frame: Up to Day 18
- AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 18
- AUClast of rosuvastatin in the presence of ecopipamTime frame: Up to Day 18
- AUClast of rosuvastatin in the absence of ecopipamTime frame: Up to Day 18
- AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 18
- AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health Clinical Research Services, LLC.
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.